Morepen Laboratories
- Market cap
- ₹ 6,754 Cr.
- P/E
- 36.6x
- P/B
- 5.17x
- 52-week range
- 33.05 – 150.7
- ROE
- 6%
- ROCE
- 8%
- Dividend yield
- 0.2%
- Debt / equity
- 0.17
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Morepen Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)36.6 against a typical 34.6: pricier than most peers (1st = cheapest).120th of 220
- Sales growth+34.1% against a typical +15.6% from a year earlier.49th of 197
- Profit growth+409.1% against a typical +18.9% from a year earlier.12th of 160
- Share price, 3 months+120.9% against a typical −0.5%.3rd of 200
- Size₹ 6,753.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).48th of 199
Latest announcements
Exchange filings and their impact on the company.
- 27 Oct 2026Outcome of Board MeetingHigh impactVery positiveQ2 revenue up 81% and profit up 118% with margins doubling and Rs 317 cr contingent liability removed.
Morepen Laboratories reported very strong Q2 FY27 consolidated results with revenue of Rs 746.5 crore, up 81% from last year, and net profit of Rs 88.9 crore, up 118%. For the first half, revenue was Rs 1316.6 crore and net profit was Rs 145.3 crore, already above full FY26 profit. The company also disclosed that on 14 October 2026 the Himachal Pradesh High Court quashed a Rs 117.94 crore GST demand, removing a Rs 317.37 crore contingent liability.
- 14 Oct 2026General UpdatesHigh impactPositiveHP High Court quashed Rs 118 cr GST refund demand, removing a profit-sized liability overhang.
Morepen Laboratories said the Himachal Pradesh High Court on 12 October 2026 quashed a Central GST show cause notice seeking recovery of Rs 117.94 crore towards excess GST refund plus interest and penalty. The order, received on 14 October 2026, decides the writ petition in the company's favour. This removes a large contingent liability equal to more than a year's profit and clears a major cash-flow overhang.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by Infomerics- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Infomerics | IVR A- | Stable | 22 Aug 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 22 Aug 2025 | New rating | IVR A- | — | Infomerics | ₹ 225 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 4 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 26 May 2026 | Financial Results/Dividend/Other business matters | MOREPENLAB : 26-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 22, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 26, 2026, To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 10 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results | To consider and approve un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30th September 2025 |
| 6 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating Profit | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% |
| Other Income | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| Profit before tax | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% |
| Net Profit | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS in Rs | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.2 | 0.75 | 0.5 | 0.29 | 1.03 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 14%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 9%
- 10 Years
- 16%
- 5 Years
- −5%
- 3 Years
- 24%
- TTM
- 27%
- 10 Years
- 17%
- 5 Years
- 13%
- 3 Years
- 37%
- TTM
- —
- 10 Years
- 12%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Morepen Laboratories | ₹ 127.80 | ₹ 6,754 Cr. | 36.6x | 5.2x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sushil Suri
- Executive Chairman of the Board, Managing Director
- Ajay Kumar Sharma
- Chief Financial Officer
- Vipul Kumar Srivastava
- Compliance Officer, Company Secretary
- Sanjay Suri
- Managing Director
Prices are delayed and for information only. Nothing on this page is investment advice.